Quotient Bioresearch, a UK provider of early phase drug development and sports testing services is to buy three spectrometers from Thermo Fisher Scientific.
The new Thermo Scientific LTQ Orbitrap XL mass spectrometers are to be aims to offer pharma businesses access to improved metabolite profiling technology.
FDA guidance is increasingly driving the need to identify and quantitate key metabolites at the early stage of the drug development process. In recognition of this guidance, Quotient Bioresearch is investing in improved metabolite profiling technology, better coordination of human AME studies, through its radio synthesis group, and an enhanced metabolite identification capability.
The LTQ Orbitrap XL combines mass resolution with high sensitivity MS/MSn performance. These capabilities support small molecule metabolite profiling and identification studies and offer a number of significant benefits such as speed, efficiency and flexibility; allowing accurate mass data on drugs and metabolites to be produced in almost half the time. In addition, the LTQ Orbitrap also offers exciting opportunities to extract metabolite information out of early toxicology and clinical research samples.